Uncategorized

Medical Services Companies Showing Strong Earnings

May 31, 2013 TM Richards 0

Healthcare has been one of the hottest sectors over the past year. This can be seen by looking at various ETFs such as iShares Dow Jones US Healthcare (IYH). This particular ETF has appreciated by approximately 35% over the past 52 weeks which is significantly higher than the 27% appreciation that the S&P Depository Receipts (SPY) has given investors. Now the healthcare sector is built up of many smaller industries and this article will focus on medical services companies which have produced strong quarterly results.

Company Snapshot — Fibrocell Science: Autologous Cell Therapy, Aesthetic Treatment

May 26, 2013 OneMedPlace Team 0

The fibroblast cell is known to play key roles in extracellular matrix synthesis, production of collagen, and production of growth factors all of which support the skin, soft tissues, and aid in wound healing. Fibrocell Science (FCSC) is an autologous cell therapy company whose sole focus is the development of aesthetic, medical, and scientific application that involve the use of the fibroblast cell.

Company Snapshot — Oxygen Biotherapeutics: Tissue Oxygenation, Traumatic Brain Injury

May 26, 2013 OneMedPlace Team 0

Oxygen is one of the main elements vital to human survival. Oxygen Biotherapeutics’ (OXBT) mission is to research, develop, and market oxygen related products based on perflurocarbons technology. The team is driven to aid the human body in maintaining adequate oxygen levels to prevent disease and damage to tissues if oxygen flow were ever to be interrupted or inhibited.

ISTO Technologies CFO: No Other Company Can Grow Living Cartilage in a Lab Setting

April 30, 2013 OneMedPlace Team 0

ISTO Technologies has a unique pipeline that has demonstrated both clinical progress and market success. With one commercialized product — a bone graft extender and substitute — and two late-stage clinical programs focusing in engineering cartilage tissue for knee and back, respectively, the company is poised to capture an opportunistic yet untapped market. OneMedRadio spoke with CFO Scott Gill about market opportunity, and finding success in a notoriously unfriendly space.

DelMar IPO Obscurity Could Offer Investors Favorable Entry

April 26, 2013 OneMedPlace Contributor 0

DelMar Pharmaceuticals (DMPI.OB) started 2013 with a revealing corporate update on January 8th. In the update, president and CEO Jeffrey Bacha outlined his goals with an exciting year ahead for the company and its employees. Mr. Bacha focused primarily on the company’s lead product candidate, VAL-083, a small molecule (chemotherapy) agent that DelMar is developing in a dose escalation trial for recurrent glioblastoma multiforme (GBM).

Idrasil: The First Medical Marijuana Pill, and Parallels in Opiate Market

April 24, 2013 OneMedPlace Team 0

California-based C3 International has brought to market the first medical marijuana pill, known as Idrasil. OneMedRadio spoke with C3 International Chairman Steele Clarke Smith III about the unique delivery technology behind Idrasil, and trends in the sector related to market opportunity, necessity for non-inhaled delivery and dialogue in the medical community.